LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia

Media type: E-Article
Title: LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia
Contributor: Rader, Daniel J; Maratos-Flier, Eleftheria; Nguyen, Amanda; Hom, Doug; Ferriere, Michael; Li, Yifang; Kompa, Jill; Martic, Miljen; Hinder, Markus; Basson, Craig T; Yowe, David; Diener, John; Goldfine, Allison B; Bajaj, Archna; Escalon, Maricer; Fein, Melanie; Hunt, Allen; Kankam, Martin K; Koren, Michael; Rader, Daniel J; Wilson, Jessica
imprint: The Endocrine Society, 2022
Published in: The Journal of Clinical Endocrinology & Metabolism
Language: English
DOI: 10.1210/clinem/dgab624
ISSN: 1945-7197; 0021-972X
Keywords: Biochemistry (medical) ; Clinical Biochemistry ; Endocrinology ; Biochemistry ; Endocrinology, Diabetes and Metabolism
Origination:
Footnote:
Description: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>To evaluate the safety and potential efficacy of LLF580, a genetically engineered variant of human fibroblast growth factor-21, for triglyceride lowering, weight loss, and hepatic fat reduction.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A multicenter, double-blind, parallel design trial in obese, mildly hypertriglyceridemic adults randomized (1:1) to LLF580 300 mg or placebo subcutaneously every 4 weeks for 3 doses.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Of 64 randomized study participants, 61 (mean ± SD: age 45 ± 11 years, 49% male, 80/15/5% Caucasian/African American/other, body mass index 36.1 ± 3.8 kg/m2) received LLF580 (n = 30) or placebo (n = 31) at 7 research sites in the United States. LLF580 lowered serum triglycerides by 54% (least square mean placebo adjusted change from baseline), total cholesterol 7%, low-density lipoprotein cholesterol 12%, and increased high-density lipoprotein cholesterol 36% compared with placebo (all P &lt; 0.001) over 12 weeks. Substantial reduction of liver fat of 52% over placebo (P &lt; 0.001) was also demonstrated in the setting of improved liver function tests including alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase, the composite enhanced liver fibrosis score, and N-terminal type III collagen propeptide (all P &lt; 0.05). Insulin and C-peptide levels and insulin resistance by homeostatic model assessment for insulin resistance were all lower, and adiponectin higher with LLF580 treatment compared with placebo, whereas fasting glucose and glycated hemoglobin were unchanged. Reductions in biomarkers of bone formation without differences in markers of bone resorption were observed. LLF580 was generally safe and well tolerated, except for higher incidence of generally mild to moderate gastrointestinal adverse effects.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>In obese, mildly hypertriglyceridemic adults, LLF580 was generally safe and demonstrated beneficial effects on serum lipids, liver fat, and biomarkers of liver injury, suggesting it may be effective for treatment of select metabolic disorders including hypertriglyceridemia and nonalcoholic fatty liver disease. Assessments of longer term safety and efficacy are warranted.</jats:p> </jats:sec> <jats:sec> <jats:title>ClinicalTrials.gov Identifier</jats:title> <jats:p>NCT03466203</jats:p> </jats:sec>
Access State: Open Access

Search in field:

Recently searched for: